Brazilian and French researchers have developed an imaging-based AI tool to predict how multiple sclerosis patients will respond to natalizumab treatment.
Key Details
- 1Combines high-content cell imaging and machine learning to analyze patient blood samples before natalizumab therapy.
- 2Study used over 400 cell morphological features, with 130 key characteristics for prediction.
- 3Tool achieved 92% accuracy in discovery and 88% in validation cohorts for predicting drug response.
- 4Non-responders showed distinct actin remodeling and cell morphology (more elongated CD8+ T cells).
- 5Findings published in Nature Communications, suggesting potential for broader disease and drug applications.
Why It Matters
This research demonstrates how imaging AI and advanced cell analysis can enable more personalized and effective treatment strategies in neurology. Such approaches could optimize resource use, reduce side effects, and accelerate precision medicine adoption in radiology and adjacent fields.
Source
EurekAlert
Related News
•EurekAlert
New Daydreaming Algorithm Boosts Neural Networks' Recall of Biased Image Data
Researchers unveil a new 'Centered Daydreaming' algorithm enabling AI to effectively learn and recall from imbalanced, real-world image data.
•EurekAlert
Polymer-Based Flexible Wireless Sensors: AI-Driven Health Monitoring Review
A major review highlights how advanced polymer-based flexible wireless sensors, enhanced by AI-driven data processing, can transform continuous physiological health monitoring.
•EurekAlert
PET Imaging Uncovers Synaptic Loss Patterns in Schizophrenia
A major PET imaging study reveals widespread, non-random synaptic loss in schizophrenia, distinct from brain volume changes seen on MRI.